Home - Translational Lung Cancer Research

Lung cancer screening

This special series gives an overview of current evidence and addresses a number of relevant questions related to the implementation of lung cancer screening. We specifically have a close look at the target population, the role of the radiologist in lung cancer screening, diagnosis and management of screen-detected nodules in Asia and Europe, the current role of sublobar resection, implantation of screening programs and finally, the psychological impact of lung cancer screening.

Radiotherapy in thoracic malignancies

In this series of Translational Lung Cancer Research, a group of renowned world experts presents the comprehensive and timely review of state-of-the-art radiation therapy in lung cancer and other thoracic malignancies.

Reviewer of the Month (2020-21)

Over the years, many TLCR reviewers have made outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Implementation of CT-based screening of lung cancer

In this special series, a group of the most outstanding experts and researchers of all aspects of lung cancer screening answers the most important questions about the introduction of a screening program as well as the development of this new field of medicine.

Multimodal Management of Locally Advanced N2 Non-small Cell Lung Cancer

This special series on “Multimodal management of locally advanced N2 non-small cell lung cancer” is edited by Dr. Mariano Provencio.

TLCR Annual Report 2020

Welcome to the 2020 annual report for Translational Lung Cancer Research. In 2020, the TLCR has continued its mission to increase the quality and impact of the journal, and to provide readers with a novel, well-organized, informative, enlightening and educational journal.

We would like to sincerely thank our Editorial Board Members, Guest editors, Reviewers, Authors, Readers for all your supports and contributions to TLCR in 2020, and we look forward to continuing our work with you in the new year.

Translational Lung Cancer Research to publish monthly beginning in January 2021

Since its initiation in 2012, Translational Lung Cancer Research (TLCR) has been developing at a speedy pace with increasing readership and citations. In order to better serve the growing needs of readers and authors, the TLCR will move from a bimonthly to a monthly publication schedule beginning in January 2021.

Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions

A deeper understanding of innate/acquired resistance to the different TKIs already available for clinical use and the development of new effective treatment strategies to overcome it, represent a current area of intense investigation and has been extensively debated within different papers published in the series.

‹ ›

Vol 10, No 5 (May, 2021)

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: editor@tlcr.org
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Original Article

Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer

Cheol-Kyu Park, Hyung-Joo Oh, Min-Seok Kim, Bo-Gun Koh, Hyun-Ju Cho, Young-Chul Kim, Hyung-Jeong Yang, Ji-Young Lee, Sung-Min Chun, In-Jae Oh

PDF Pages: 2103-2117 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies

Petros Christopoulos, Steffen Dietz, Arlou K. Angeles, Stephan Rheinheimer, Daniel Kazdal, Anna-Lena Volckmar, Florian Janke, Volker Endris, Michael Meister, Mark Kriegsmann, Thomasz Zemojtel, Martin Reck, Albrecht Stenzinger, Michael Thomas, Holger Sültmann

PDF Pages: 2118-2131 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Characteristics of hypoxic tumor microenvironment in non-small cell lung cancer, involving molecular patterns and prognostic signature

Zhanghao Huang, Shuo Wang, Hai-Jian Zhang, You Lang Zhou, Xin Tang, Jia-Hai Shi

PDF Pages: 2132-2147 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors

Jiebai Zhou, Yencheng Chao, Danwei Yao, Ning Ding, Jiamin Li, Lei Gao, Yong Zhang, Xiaobo Xu, Jian Zhou, Balazs Halmos, Nikolaos Tsoukalas, Yuki Kataoka, Ramon Andrade de Mello, Yuanlin Song, Jie Hu

PDF Pages: 2148-2162 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy

Xun Yuan, Zhiqin Zheng, Fangfang Liu, Yuan Gao, Wenhui Zhang, Rossana Berardi, Pranshu Mohindra, Zhengfei Zhu, Jie Lin, Qian Chu

PDF Pages: 2163-2171 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

M⁵C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma

Hui Chen, Xiao-Lin Ge, Zhao-Yue Zhang, Ming Liu, Rui-Yan Wu, Xiao-Fei Zhang, Li-Ping Xu, Hong-Yan Cheng, Xin-Chen Sun, Hong-Cheng Zhu

PDF Pages: 2172-2192 Full Text Reporting Checklist COI Form Open Access

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer

Yulong Chen, Bo Yan, Feng Xu, Zhenzhen Hui, Gang Zhao, Jie Liu, Huan Zhang, Ziqing Zeng, Ran Zhang, Mariano Provencio, Xiubao Ren, Jian You

PDF Pages: 2193-2204 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Risk stratification model for patients with stage I invasive lung adenocarcinoma based on clinical and pathological predictors

Yiyang Wang, Difan Zheng, Jizhuang Luo, Jie Zhang, Cecilia Pompili, Hideki Ujiie, Natsumi Matsuura, Haiquan Chen, Feng Yao

PDF Pages: 2205-2217 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Hybrid stenting with silicone Y stents and metallic stents in the management of severe malignant airway stenosis and fistulas

Yu Chen, Zi-Qing Zhou, Jia-Xin Feng, Zhu-Quan Su, Chang-Hao Zhong, Li-Ya Lu, Xiao-Bo Chen, Chun-Li Tang, Subba R. Digumarthy, Alfonso Fiorelli, Ehsan Natour, Filippo Lococo, Francesco Petrella, Kassem Harris, Takeo Nakada, Nan-Shan Zhong, Shi-Yue Li

PDF Pages: 2218-2228 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Preoperative computer tomography-guided indocyanine green injection is associated with successful localization of small pulmonary nodules

Xukai Li, Ke Xu, Renli Cen, Jinghui Deng, Zhexue Hao, Jun Liu, Hiromitsu Takizawa, Calvin S. H. Ng, Giuseppe Marulli, Min P. Kim, Fei Cui, Jianxing He

PDF Pages: 2229-2236 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Review Article

Liquid biopsy in non-small cell lung cancer—current status and future outlook—a narrative review

Elisabeth Smolle, Valentin Taucher, Jörg Lindenmann, Martin Pichler, Freyja-Maria Smolle-Juettner

PDF Pages: 2237-2251 Full Text Reporting Checklist Peer Review File COI Form Open Access

Role of lymphatic endothelial cells in the tumor microenvironment—a narrative review of recent advances

Miao He, Qihua He, Xiuyu Cai, Zisheng Chen, Shen Lao, Hongsheng Deng, Xiwen Liu, Yongmei Zheng, Xiaoyan Liu, Jun Liu, Zhanhong Xie, Maojin Yao, Wenhua Liang, Jianxing He

PDF Pages: 2252-2277 Full Text Reporting Checklist Peer Review File COI Form Open Access

Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials

Hiromi Matsumoto, Nobuyuki Horita, Kentaro Ito, Risa Ebina-Shibuya, Yu Hara, Nobuaki Kobayashi, Takeshi Kaneko

PDF Pages: 2278-2289 Full Text Reporting Checklist COI Form Open Access

Case Report

A novel lung autotransplantation technique for treating central lung cancer: a case report

Jiaxi He, Chao Yang, Hon Chi Suen, Jianxing He, Shuben Li

PDF Pages: 2290-2297 Full Text Reporting Checklist Peer Review File COI Form Open Access

Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report

Shuai Zhu, Shikang Zhao, Qian Zhang, Shuo Li, Dian Ren, Fan Ren, Lingling Zu, Yanye Wang, Xi Lei, Ning Zhou, Tao Shi, Dongbo Xu, Gang Chen, Wan-Teck Lim, Raffaele Giusti, Abraham J. Wu, Song Xu

PDF Pages: 2298-2305 Full Text Reporting Checklist COI Form Open Access

Editorial on Lung Cancer Screening¹

Lung cancer screening: the preface

Annemiek Snoeckx, Paul E. Van Schil

PDF Pages: 2306-2308 Full Text COI Form Open Access

Review Article on Lung Cancer Screening¹

Lung cancer screening: targeting the hard to reach—a review

Guido Van Hal, Paloma Diab Garcia

PDF Pages: 2309-2322 Full Text Peer Review File COI Form Open Access

Managing screening-detected subsolid nodules—the Asian perspective

Masaaki Sato, Shun-Mao Yang, Dong Tian, Nakajima Jun, Jang-Ming Lee

PDF Pages: 2323-2334 Full Text COI Form Open Access

Screen-detected solid nodules: from detection of nodule to structured reporting

Mario Silva, Gianluca Milanese, Roberta E. Ledda, Ugo Pastorino, Nicola Sverzellati

PDF Pages: 2335-2346 Full Text COI Form Open Access

Ongoing challenges in implementation of lung cancer screening

Katharina Martini, Guillaume Chassagnon, Thomas Frauenfelder, Marie-Pierre Revel

PDF Pages: 2347-2355 Full Text COI Form Open Access

The radiologist’s role in lung cancer screening

Annemiek Snoeckx, Caro Franck, Mario Silva, Mathias Prokop, Cornelia Schaefer-Prokop, Marie-Pierre Revel

PDF Pages: 2356-2367 Full Text COI Form Open Access

Managing of screening-detected sub-solid nodules—a European perspective

Sara Ricciardi, Richard Booton, Renè Horsleben Petersen, Maurizio Infante, Marco Scarci, Giulia Veronesi, Giuseppe Cardillo

PDF Pages: 2368-2377 Full Text COI Form Open Access

Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice?

Anton Schreuder, Ernst T. Scholten, Bram van Ginneken, Colin Jacobs

PDF Pages: 2378-2388 Full Text COI Form Open Access

Lung cancer screening: who pays? who receives?—the Chinese perspective

Yang Zhang, Haiquan Chen

PDF Pages: 2389-2394 Full Text COI Form Open Access

Lung cancer screening: who pays? Who receives? The European perspectives

Pierluigi Novellis, Silvia Raimondi Cominesi, Francesca Rossetti, Michele Mondoni, Vanesa Gregorc, Giulia Veronesi

PDF Pages: 2395-2406 Full Text Peer Review File COI Form Open Access

Lung cancer screening in Europe: where are we in 2021?

Jan P. van Meerbeeck, Caro Franck

PDF Pages: 2407-2417 Full Text COI Form Open Access

Should sublobar resection be offered for screening-detected lung nodules?

Alan D. L. Sihoe

PDF Pages: 2418-2426 Full Text COI Form Open Access

The person behind the nodule: a narrative review of the psychological impact of lung cancer screening

Samantha L. Quaife, Samuel M. Janes, Kate E. Brain

PDF Pages: 2427-2440 Full Text Reporting Checklist Peer Review File COI Form Open Access

Disclosure:

1. The series “Lung cancer screening” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Paul van Schil and Annemiek Snoeckx served as the unpaid Guest Editors for the series.

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Editorial

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Daniel B. Costa, Susumu S. Kobayashi

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa, Shaker A. Mousa

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Po Yee Yip

Lung cancer molecular epidemiology in China: recent trends

Caicun Zhou

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Cristina Teixidó, Niki Karachaliou, Vicente Peg, Ana Gimenez-Capitan, Rafael Rosell

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo, Francesco Passiglia, Marta Castiglia, Luis E. Raez, Paul Germonpre, Ignacio Gil-Bazo, Karen Zwaenepoel, Annemieke De Wilde, Giuseppe Bronte, Antonio Russo, Jan P. Van Meerbeeck, Paul Van Schil, Patrick Pauwels

Highlighted Reports in European Lung Cancer Conference

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Paul De Leyn, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Charles B. Simone II, Stuart H. Burri, John H. Heinzerling

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis

Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song

BRAF mutations in non-small cell lung cancer

Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer

Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice

Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer

Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants

Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices

Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim, Jin-Haeng Chung

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer

Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Clinical trials for lung cancer in China

Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Prognostic markers in lung cancer: is it ready for prime time?

Chang-Qi Zhu, Ming-Sound Tsao

Potential biomarkers for lung cancer screening

Gabriella Sozzi, Mattia Boeri

Particle therapy in non-small cell lung cancer

Zhongxing Liao, Charles B. Simone II

Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions

Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Suchit H. Patel, Andreas Rimner, Roger B. Cohen

Intraoperative near-infrared imaging of mesothelioma

Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal

BAP1, a tumor suppressor gene driving malignant mesothelioma

Mitchell Cheung, Joseph R. Testa

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Jordan Dozier, Hua Zheng, Prasad S. Adusumilli

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer

Linda O’Flaherty, Harriet Wikman, Klaus Pantel

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Sumitra Mohan, Francesca Chemi, Ged Brady

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Derrick W. Su, Jorge Nieva

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Editorial

An alternative way to initiate Notch1 signaling in non-small cell lung cancer

Yi-Lin Yang, David Jablons, Liang You

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C. Santini, Siddharth Kunte, Alexander Drilon

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis

Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

China Lung Cancer Research Highlight

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Maria Felice Brizzi, Paola Defilippi

Editorials

Dulanermin in cancer therapy: Still much to do

Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr

Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review

Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Ceritinib

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Daniel B. Costa

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack

Lorenza Landi, Federico Cappuzzo

Nivolumab

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

Arun Rajan, James L. Gulley

Brief Report

The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial

Ying Xiao, Mark Rosen

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hyo Sup Shim

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article

Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

Hiroyuki Inoue, Hirono Tsutsumi, Kentaro Tanaka, Eiji Iwama, Yoshimasa Shiraishi, Aiko Hirayama, Takayuki Nakanishi, Hiroyuki Ando, Maako Nakajima, Seiji Shinozaki, Hiroaki Ogata, Kazuyasu Uryu, Koji Okamura, Shinichi Kimura, Tomohiro Ogawa, Keiichi Ota, Yasuto Yoneshima, Naoki Hamada, Yoichi Nakanishi, Isamu Okamoto

Should resection extent be decided by total lesion size or solid component size in ground glass opacity-containing lung adenocarcinomas?

Boyu Lin, Rui Wang, Liang Chen, Zhitao Gu, Chunyu Ji, Wentao Fang

Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study

Myeong Geun Choi, Chang-Min Choi, Dae Ho Lee, Sang-We Kim, Shinkyo Yoon, Woo Sung Kim, Wonjun Ji, Jae Cheol Lee

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit

Yusuke Tomita, Bryan Oronsky, Nacer Abrouk, Pedro Cabrales, Tony R. Reid, Min-Jung Lee, Akira Yuno, Jonathan Baker, Sunmin Lee, Jane B. Trepel

PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer

Fei Wu, Yanzi Gu, Bin Kang, Fabienne Heskia, Alexandre Pachot, Marc Bonneville, Ping Wei, Ji Liang

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit

Yusuke Tomita, Bryan Oronsky, Nacer Abrouk, Pedro Cabrales, Tony R. Reid, Min-Jung Lee, Akira Yuno, Jonathan Baker, Sunmin Lee, Jane B. Trepel

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis

Giorgia Guaitoli, Marcello Tiseo, Massimo Di Maio, Luc Friboulet, Francesco Facchinetti

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse

Haoyue Guo, Li Diao, Xiaofeng Zhou, Jie-Neng Chen, Yue Zhou, Qiyu Fang, Yayi He, Rafal Dziadziuszko, Caicun Zhou, Fred R. Hirsch

Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis

Michael Dorry, Kevin Davidson, Rajesh Dash, Rachel Jug, Jeffrey M. Clarke, Andrew B. Nixon, Kamran Mahmood

One carbon metabolism in human lung cancer

Sha Yao, Luogen Peng, Omar Elakad, Stefan Küffer, Marc Hinterthaner, Bernhard C. Danner, Alexander von Hammerstein-Equord, Philipp Ströbel, Hanibal Bohnenberger

The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer

Yong Seok Lee, Jun Hyeok Lim, Wookyung Ryu, Mi Hwa Park, Lucia Kim, Kang Kim, Woo Youl Kim, Hae-Seong Nam

First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis

Francesco Facchinetti, Massimo Di Maio, Fabiana Perrone, Marcello Tiseo

Review Article

Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer

Steven Bozinovski, Amanda Vannitamby, Kanishka Rangamuwa, Savreet Aujla, Hao Wang, Christian Aloe, Louis Irving, Tracy T. Leong, Daniel P. Steinfort

Immunotherapy in small cell lung cancer: one step at a time: a narrative review

Daphne W. Dumoulin, Anne-Marie C. Dingemans, Joachim G. J. V. Aerts, Jordi Remon, Dirk K. M. De Ruysscher, Lizza E. L. Hendriks

Immunotherapy in oncogene addicted non-small cell lung cancer

Luke McLean, Jose Luis Leal, Benjamin J. Solomon, Thomas John

Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors

Kanishka Rangamuwa, Tracy Leong, Clare Weeden, Marie-Liesse Asselin-Labat, Steven Bozinovski, Michael Christie, Tom John, Phillip Antippa, Louis Irving, Daniel Steinfort

Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review

Luca Bertolaccini, Monica Casiraghi, Giulia Sedda, Filippo de Marinis, Lorenzo Spaggiari

The multiple roles and therapeutic potential of clusterin in non-small-cell lung cancer: a narrative review

Juofang Tan, Wei Guo, Su Yang, Dingpei Han, Hecheng Li

Immunotherapy in malignant pleural mesothelioma: a review of literature data

Jessica Menis, Giulia Pasello, Jordi Remon

Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer? A narrative review

Wolfram C. M. Dempke, Klaus Fenchel

Current and future research efforts in oligometastatic non-small cell lung cancer—a systematic review

Mariana Brandão, Valérie Durieux, Thierry Berghmans

Emerging and multifaceted role of neutrophils in lung cancer

Christian Aloe, Hao Wang, Ross Vlahos, Louis Irving, Daniel Steinfort, Steven Bozinovski

A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done

Lorenzo Belluomini, Alessandra Dodi, Alberto Caldart, Dzenete Kadrija, Marco Sposito, Miriam Casali, Giulia Sartori, Miriam Grazia Ferrara, Alice Avancini, Emilio Bria, Jessica Menis, Michele Milella, Sara Pilotto

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations

Roberto Ferrara, Diego Signorelli, Claudia Proto, Arsela Prelaj, Marina Chiara Garassino, Giuseppe Lo Russo

B cells in lung cancer—not just a bystander cell: a literature review

Tracy L. Leong, Vanessa L. Bryant

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review

Michael C. Tjong, Alexander V. Louie, Puneeth Iyengar, Benjamin J. Solomon, David A. Palma, Shankar Siva

Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review

Vincent Fallet, Lise Matton, Antoine Schernberg, Anthony Canellas, François H. Cornelis, Jacques Cadranel

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?

Lizza E. L. Hendriks, Jordi Remon, Jessica Menis, Benjamin Besse

Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer

Boris Duchemann, Jordi Remon, Marie Naigeon, Lydie Cassard, Jean Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Edouard Auclin, Aude Desnoyer, Benjamin Besse, Nathalie Chaput

Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease

Francesco Passiglia, Valeria Cetoretta, Marco De Filippis, Valerio Napoli, Silvia Novello

Exploring natural killer cell immunology as a therapeutic strategy in lung cancer

Jonas B. Hess, Kate D. Sutherland, Sarah A. Best

Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review

Nora Sundahl, Yolande Lievens

A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer

Zarique Z. Akanda, Paul J. Neeson, Thomas John, Stephen Barnett, Gerard G. Hanna, Alistair Miller, Ross Jennens, Shankar Siva

How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review

Jordi Remon, Jessica Menis, Antonin Levy, Dirk K. M. De Ruysscher, Lizza E. L. Hendriks

The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review

Alistair R. Miller, Renee Manser

Holding our breath: the promise of tissue-resident memory T cells in lung cancer

Claire Marceaux, Clare E. Weeden, Claire L. Gordon, Marie-Liesse Asselin-Labat

Editorial

Local for advanced, is this a paradox?

Maristella Bungaro, Chiara Paratore, Paolo Bironzo, Silvia Novello

Erratum

Erratum to pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report

Editorial Office

Brief Report

Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation

Kanishka Rangamuwa, Tracy Leong, Steven Bozinovski, Michael Christie, Thomas John, Phillip Antippa, Louis Irving, Daniel Steinfort

Editorial on Lung Cancer and The Immune System

Lung cancer and the immune system—current controversies and future opportunities

Daniel P. Steinfort

Editorial on Immunotherapy in Other Thoracic Malignancies and Uncommon Populations

Immunotherapy in other thoracic malignancies and uncommon populations

Jordi Remon, Benjamin Besse

Journal Highlight more

Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.